Monographie - Thiotepa - Stabilis 4.0

Utolsó frissítés :
19/11/2024

rákellenes gyógyszer

Thiotepa

Injekció

Az oldatok stabilitása

A keverékek stabilitása

Stabilitást befolyásoló tényezők

Kompatibilitás

Az alkalmazás módja

Irodalom

pdf

Kémiai szerkezet

Kereskedelmi név

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Bedford	új-Zéland
Ledertepa	Hollandia
Oncotiotepa	Spanyolország
Thioplex	Olaszország
Thiotepa	Amerikai Egyesült Államok, Ausztrália, Ausztria, Írország, Nagy-Britannia, Németország, Svédország

Irodalom

Injekció

Irodalom : Thiotepa

	Type	publikáció
3	Napló	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Napló	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Napló	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Napló	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Napló	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Napló	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
302	Napló	Murray KM, Erkkila D, Gombotz WR, Pankey S. Stability of thiotepa (lyophilized) in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1997 ; 54: 2588-2591.
307	Napló	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
905	Napló	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
3603	Laboratórium	Thiotepa (Tepadina®) - Summary of Product Characteristics Adienne Pharma Biotech 2011
4677	poszter	Linxweiler H, Thiesen J, Krämer I. Physicochemical stability of diluted "Thiotepa Riemser" infusion solutions in prefilled 5% glucose infusion bags. EAHP Congress Vienna 2022
4748	Napló	Linxweiler H, Thiesen J, Krämer I. Physicochemical Stability of Generic Thiotepa Concentrate and Ready-to-Administer Infusion Solutions for Conditioning Treatment. Pharmaceutics 2023 ,15, 309.

Mentions Légales